Strong Third Quarter Results
Revenue, margin performance, and earnings per share all significantly exceeded expectations. Sales were well above the high end of guidance range, with each reported region returning to positive growth.
Instrument and Recurring Revenue Growth
Instruments grew 1% after seven quarters of decline, led by pharma and industrial end markets. Recurring revenue grew 7%, with an 8% increase in chemistry consumables.
Improved Operational Performance
Gross margin expanded by 20 basis points to 59.3%, and adjusted operating margin was a solid 30.8%.
Innovative Product Success
The Xevo TQ Absolute saw over 70% year-over-year growth in customer adoption and became the best-selling mass spectrometer in the quarter.
Strong Position in High-Growth Markets
GLP-1 and PFAS testing contributed significantly to growth, with GLP-1 products being a major part of commercially available injectables.